BIOMAT Database Logo BIOMAT Database Logo

Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. 1995

N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Second Department of Internal Medicine, School of Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.

Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals. However, the exact mechanism of Troglitazone on the improvement of insulin resistance is not known. Chronic administration of fructose to normal rats leads to hyperglycemia, and hyperinsulinemia; it induces insulin resistance. To reveal the mechanism of Troglitazone, we studied the effect of Troglitazone on serum glucose and insulin in the fructose-induced, insulin-resistant rats. Male Sprague-Dawley (SD) rats were fed either on standard chow or one containing fructose. Troglitazone was administrated as a food admixture (150 mg/kg/day) for 8 weeks. The rats were fed on (1) standard chow, (2) standard chow and Troglitazone, (3) fructose-enriched chow, or (4) fructose-enriched chow and Troglitazone. Blood samples were obtained every two weeks, and the levels of serum glucose and insulin were measured. Fructose-enriched chow increased serum glucose and insulin levels and insulin-to-glucose ratios. Troglitazone improved the fructose-induced increases in serum glucose, insulin levels, and insulin/glucose ratios. In conclusion, Troglitazone improved the fructose-induced insulin resistance.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast
D006946 Hyperinsulinism A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS. Compensatory Hyperinsulinemia,Endogenous Hyperinsulinism,Exogenous Hyperinsulinism,Hyperinsulinemia,Hyperinsulinemia, Compensatory,Hyperinsulinism, Endogenous,Hyperinsulinism, Exogenous
D000077288 Troglitazone A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T,CS 045,CS-045,Prelay,Rezulin,CS045

Related Publications

N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Troglitazone (CS-045): a new antidiabetic agent.
May 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Troglitazone, a new antidiabetic agent, decreases cyclosporine level.
November 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
December 1994, Diabetes,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Troglitazone: an antidiabetic agent.
May 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Effect of the new oral antidiabetic agent (-)-BM 13.0913.Na on insulin resistance in lean and obese Zucker rats.
May 1995, Metabolism: clinical and experimental,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
[Effect of oral antidiabetic agents on fructose biosynthesis].
January 2000, Eksperimental'naia i klinicheskaia farmakologiia,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Antidiabetic effect of hydroalcholic urticadioica leaf extract in male rats with fructose-induced insulin resistance.
September 2012, Iranian journal of medical sciences,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance.
December 1999, Bioorganic & medicinal chemistry letters,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
A new oral antidiabetic agent: sucrida.
February 1960, Canadian Medical Association journal,
N Yagi, and N Takasu, and S Higa, and K Ishikawa, and K Murakami, and G Mimura
Gondafon--a new oral antidiabetic agent.
May 1967, Drug and therapeutics bulletin,
Copied contents to your clipboard!